JP2021519288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021519288A5 JP2021519288A5 JP2020551496A JP2020551496A JP2021519288A5 JP 2021519288 A5 JP2021519288 A5 JP 2021519288A5 JP 2020551496 A JP2020551496 A JP 2020551496A JP 2020551496 A JP2020551496 A JP 2020551496A JP 2021519288 A5 JP2021519288 A5 JP 2021519288A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- placebo
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000000902 placebo Substances 0.000 claims 7
- 229940068196 placebo Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- TXKRWVMEUQBFSO-UHFFFAOYSA-N sulfuric acid;trihydrate Chemical class O.O.O.OS(O)(=O)=O TXKRWVMEUQBFSO-UHFFFAOYSA-N 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 206010027603 Migraine headaches Diseases 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000004067 bulking agent Substances 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023116385A JP2023134690A (ja) | 2018-03-25 | 2023-07-18 | Ｃｇｒｐ関連障害のためのリメゲパント |
| JP2026069265A JP2026123097A (ja) | 2018-03-25 | 2026-04-20 | Ｃｇｒｐ関連障害のためのリメゲパント |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647794P | 2018-03-25 | 2018-03-25 | |
| US62/647,794 | 2018-03-25 | ||
| US201862664761P | 2018-04-30 | 2018-04-30 | |
| US62/664,761 | 2018-04-30 | ||
| US201862774285P | 2018-12-02 | 2018-12-02 | |
| US62/774,285 | 2018-12-02 | ||
| US201862777180P | 2018-12-09 | 2018-12-09 | |
| US62/777,180 | 2018-12-09 | ||
| US201862777625P | 2018-12-10 | 2018-12-10 | |
| US62/777,625 | 2018-12-10 | ||
| PCT/US2019/023940 WO2019191008A1 (en) | 2018-03-25 | 2019-03-25 | Rimegepant for cgrp related disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116385A Division JP2023134690A (ja) | 2018-03-25 | 2023-07-18 | Ｃｇｒｐ関連障害のためのリメゲパント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519288A JP2021519288A (ja) | 2021-08-10 |
| JP2021519288A5 true JP2021519288A5 (enExample) | 2021-12-16 |
Family
ID=68060723
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551496A Withdrawn JP2021519288A (ja) | 2018-03-25 | 2019-03-25 | Ｃｇｒｐ関連障害のためのリメゲパント |
| JP2023116385A Pending JP2023134690A (ja) | 2018-03-25 | 2023-07-18 | Ｃｇｒｐ関連障害のためのリメゲパント |
| JP2026069265A Pending JP2026123097A (ja) | 2018-03-25 | 2026-04-20 | Ｃｇｒｐ関連障害のためのリメゲパント |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023116385A Pending JP2023134690A (ja) | 2018-03-25 | 2023-07-18 | Ｃｇｒｐ関連障害のためのリメゲパント |
| JP2026069265A Pending JP2026123097A (ja) | 2018-03-25 | 2026-04-20 | Ｃｇｒｐ関連障害のためのリメゲパント |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20210000814A1 (enExample) |
| EP (3) | EP3773572A4 (enExample) |
| JP (3) | JP2021519288A (enExample) |
| KR (1) | KR20200135465A (enExample) |
| CN (1) | CN112153969A (enExample) |
| AU (1) | AU2019242604B2 (enExample) |
| BR (1) | BR112020019396A2 (enExample) |
| CA (1) | CA3094693A1 (enExample) |
| DK (1) | DK4088720T3 (enExample) |
| ES (1) | ES3047659T3 (enExample) |
| FI (1) | FI4088720T3 (enExample) |
| IL (1) | IL277272B1 (enExample) |
| MX (1) | MX2020009856A (enExample) |
| PH (1) | PH12020551425A1 (enExample) |
| PL (1) | PL4088720T3 (enExample) |
| PT (1) | PT4088720T (enExample) |
| SG (1) | SG11202009199YA (enExample) |
| SI (1) | SI4088720T1 (enExample) |
| WO (1) | WO2019191008A1 (enExample) |
| ZA (2) | ZA202006190B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4088720T3 (da) * | 2018-03-25 | 2025-09-29 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant til cgrp-relaterede lidelser |
| KR20210116560A (ko) * | 2019-01-20 | 2021-09-27 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 편두통 돌발을 치료하기 위한 cgrp 길항제 |
| CN114980862A (zh) * | 2019-12-17 | 2022-08-30 | 拜尔哈文制药股份有限公司 | Cgrp抑制剂的鼻内药物组合物 |
| CA3172358A1 (en) * | 2020-02-27 | 2021-09-02 | Biohaven Pharmaceutical Holding Company Ltd. | Oral fast-dispersing dosage form of rimegepant |
| CN115697378A (zh) * | 2020-03-23 | 2023-02-03 | 拜尔哈文制药股份有限公司 | 用cgrp抑制剂治疗肺部损伤的方法 |
| JP2023533634A (ja) * | 2020-03-29 | 2023-08-04 | バイオヘイブン・ファーマシューティカル・アイルランド・デジグネイテッド・アクティビティ・カンパニー | 片頭痛の予防的治療 |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| LT4243797T (lt) | 2020-11-16 | 2026-06-10 | Orcosa Inc. | Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| CA3202137A1 (en) * | 2020-11-19 | 2022-05-27 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
| CN117999078A (zh) * | 2021-03-02 | 2024-05-07 | Cgrp诊断公司 | 偏头痛的发生的治疗和/或降低 |
| WO2022251752A2 (en) * | 2021-05-25 | 2022-12-01 | Biohaven Pharmaceutical Ireland Dac | Dual treatment of migraine |
| CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
| WO2023055758A1 (en) * | 2021-09-29 | 2023-04-06 | Pfizer Ireland Pharmaceuticals | Preventative treatment of migraine |
| CN114010608A (zh) * | 2021-11-23 | 2022-02-08 | 莱默(北京)药业科技有限公司 | 一种瑞美吉泮冻干口崩片及制备方法 |
| CN115154469A (zh) * | 2022-07-22 | 2022-10-11 | 中国科学院广州生物医药与健康研究院 | 瑞美吉泮或其药学上可接受的盐在制备预防或治疗肥胖的药物中的应用 |
| WO2024062504A1 (en) * | 2022-09-22 | 2024-03-28 | Quisitive Therapeutics | Pharmaceutical composition comprising ubrogepant and administration thereof |
| WO2024211881A1 (en) * | 2023-04-06 | 2024-10-10 | Navinta, Llc | Rimegepant suspension |
| WO2024220974A1 (en) * | 2023-04-21 | 2024-10-24 | Navinta, Llc | Rimegepant fast-dissolving films for oral administration |
| CN117414352A (zh) * | 2023-11-22 | 2024-01-19 | 湖北广济医药科技有限公司 | 一种瑞美吉泮口溶膜剂及其制备方法 |
| WO2025193980A2 (en) * | 2024-03-13 | 2025-09-18 | CNS Biosciences, Inc. | Method of treating neuropathic pain using an anti-cgrp inhibitor |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US7704583B2 (en) | 1998-08-14 | 2010-04-27 | R.P.Scherer Technologies, Inc. | Embossed blister pack |
| GB9817793D0 (en) | 1998-08-14 | 1998-10-14 | Scherer Corp R P | The formation of indicia in the base of a blister pack for transference to a body cast therein |
| GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| CA2615463A1 (en) * | 2005-07-29 | 2007-02-08 | Merck & Co., Inc. | Heterocyclic benzodiazepine cgrp receptor antagonists |
| US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
| RS56556B1 (sr) * | 2012-02-27 | 2018-02-28 | Bristol Myers Squibb Co | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so |
| US20130225336A1 (en) * | 2012-02-28 | 2013-08-29 | Edward R. Harvey | Method and apparatus for teaching the throwing of a curveball without injury |
| EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| US10117836B2 (en) * | 2014-02-05 | 2018-11-06 | Merck Sharp & Dohme Corp. | Tablet formulation for CGRP active compounds |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| DK4088720T3 (da) * | 2018-03-25 | 2025-09-29 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant til cgrp-relaterede lidelser |
| KR20210116560A (ko) * | 2019-01-20 | 2021-09-27 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 편두통 돌발을 치료하기 위한 cgrp 길항제 |
-
2019
- 2019-03-25 DK DK22182756.1T patent/DK4088720T3/da active
- 2019-03-25 KR KR1020207030358A patent/KR20200135465A/ko not_active Ceased
- 2019-03-25 EP EP19776794.0A patent/EP3773572A4/en not_active Withdrawn
- 2019-03-25 WO PCT/US2019/023940 patent/WO2019191008A1/en not_active Ceased
- 2019-03-25 JP JP2020551496A patent/JP2021519288A/ja not_active Withdrawn
- 2019-03-25 ES ES22182756T patent/ES3047659T3/es active Active
- 2019-03-25 US US16/767,134 patent/US20210000814A1/en not_active Abandoned
- 2019-03-25 MX MX2020009856A patent/MX2020009856A/es unknown
- 2019-03-25 AU AU2019242604A patent/AU2019242604B2/en active Active
- 2019-03-25 IL IL277272A patent/IL277272B1/en unknown
- 2019-03-25 PL PL22182756.1T patent/PL4088720T3/pl unknown
- 2019-03-25 EP EP22182756.1A patent/EP4088720B1/en active Active
- 2019-03-25 CN CN201980034240.4A patent/CN112153969A/zh active Pending
- 2019-03-25 PT PT221827561T patent/PT4088720T/pt unknown
- 2019-03-25 FI FIEP22182756.1T patent/FI4088720T3/fi active
- 2019-03-25 BR BR112020019396-8A patent/BR112020019396A2/pt unknown
- 2019-03-25 EP EP25192368.6A patent/EP4631944A3/en active Pending
- 2019-03-25 SI SI201930982T patent/SI4088720T1/sl unknown
- 2019-03-25 SG SG11202009199YA patent/SG11202009199YA/en unknown
- 2019-03-25 CA CA3094693A patent/CA3094693A1/en active Pending
-
2020
- 2020-05-27 US US16/884,196 patent/US11083724B2/en active Active
- 2020-09-10 PH PH12020551425A patent/PH12020551425A1/en unknown
- 2020-10-06 ZA ZA2020/06190A patent/ZA202006190B/en unknown
-
2021
- 2021-08-08 US US17/396,717 patent/US20220168295A1/en not_active Abandoned
-
2022
- 2022-05-05 ZA ZA2022/04929A patent/ZA202204929B/en unknown
-
2023
- 2023-07-18 JP JP2023116385A patent/JP2023134690A/ja active Pending
-
2026
- 2026-04-20 JP JP2026069265A patent/JP2026123097A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110003006A1 (en) | Orally Disintegrating Tablet Compositions Comprising Combinations of Non-Opioid and Opioid Analgesics | |
| CN102036656A (zh) | 含有蜡的缓释制剂 | |
| JP2023513249A5 (enExample) | ||
| JP2013511507A5 (enExample) | ||
| US12521385B2 (en) | Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications | |
| JP2008163038A (ja) | 経口抗菌医薬組成物 | |
| JP2020527575A5 (enExample) | ||
| EP1462098B1 (en) | Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin | |
| BR112022000413A2 (pt) | Formulação de longa duração contendo rivastigmina e método para preparar a mesma | |
| JP2019501207A (ja) | バレニクリンまたはこの薬学的に許容可能な塩を含有する、味の遮蔽された口腔投与用薬学製剤 | |
| EP3210599B1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
| JP2004525940A (ja) | 火照りの処置のためのデュロキセチン | |
| JP2022540348A5 (enExample) | ||
| AU2014326142B2 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| TW201739455A (zh) | 菸鹼醯胺的口服醫藥組成物 | |
| WO2022138717A1 (ja) | 経口固形製剤 | |
| CN113557016A (zh) | 衣壳组装调节剂固体配制品 | |
| CN107205942A (zh) | 包含富马酸二甲酯的药物基质制剂 | |
| KR20160105662A (ko) | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 | |
| CN105311635A (zh) | 可调控释放度的高载药量的医药组合物及其制备方法 | |
| KR20140118412A (ko) | 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물 | |
| JP5962161B2 (ja) | 耳管開放症治療剤 | |
| JP2024503689A5 (enExample) | ||
| JP2022540917A5 (enExample) | ||
| JP7581712B2 (ja) | アビラテロン酢酸エステル含有製剤 |